InvestorsHub Logo
Followers 54
Posts 6611
Boards Moderated 0
Alias Born 01/11/2017

Re: Fortuno post# 53374

Tuesday, 01/21/2020 12:15:14 PM

Tuesday, January 21, 2020 12:15:14 PM

Post# of 232709
Great to have a civilized debate! Thank you Fortunato

Do I think we will get there? Yes, I do. The science is overwhelming. For the last three years, outside factors concern me more... what are they? Trying to figure out why the FDA is slow-walking Leronlimab. It’s a no-brainer yet they find a reason to continually stall and ask for more info. There could be valid reasons. I’m not putting that on Nader directly but indirectly, he’s either not getting them what they need, understanding what they need or just doesn’t have the juice to push them around. It’s a government agency so they treat companies as they sit fit, without impunity, especially with this renegade administration.

BLA is on us. Financing is on us. Missed timelines is on us! They’re on us because they’re not on anybody else. I’m giving Nader the benefit but all he’s really gotten done was a deal with a third-rate company. Time will tell if that works out.

Most importantly, BLA continues to be delayed and delayed...by months. He just needs to say “we will submit when we can” He stated in December that it would DEFINITELY be by end of December or first week of January. We are fast-approaching February and no news. Also, I believe it was mentioned a potential $40-50M non-dilutive financing possibly. When is Nader going to learn to keep his mouth shut until the ink is dry!

Could this see $100/share? Anything is possible but I think with the current number of fully diluted shares of ~700M, that would be a $70 BILLION market cap. Taking into account how long that would take to get approval on all trials, competitors will be nipping at our heels. I think if we see $20, it would still be considered on of the greatest investment stories ever.

Grip
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News